drugset / Trial / NCT07398664
H101 Plus TACE for r/m HNSCC
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Timeline
- Start
- 2026-03-02
- Primary completion
- 2028-06-15
- Completion
- 2028-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H101 | Other / unclassified | — | — |